LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is leading a consortium that has been awarded a €4 million ($4.2 million1) grant from Horizon Europe, the European Union’s key funding program for research and innovation. The consortium, which also includes Leibniz University Hannover (the project coordinator), the Cell and Gene Therapy Catapult, and the Fundacion para la Investigacion del Hospital Universitario la Fe de la Comunidad Valenciana, will develop an innovative smart bioprocessing manufacturing platform for personalized cell therapies.
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
Globe Newswire - Thu Jul 21, 2022 Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Unitedhealth%20Group%20Inc%20HQ%20photo-by%20jetcityimage%20via%20iStock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20logo%20and%20chart%20data-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Apple%20products%20on%20desk%20by%20Ake%20Ngiamsanguan%20via%20iStock.jpg)
